Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3100315 | 0.99 | SLC6A9 (0.62) | SLC6A9SLC6A2SLC6A4SLC6A3SIGMAR1 | |
| SCHEMBL7896618 | 0.90 | SLC6A9 (0.73) | SLC6A9SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3101260 | 0.89 | SLC6A9 (0.72) | SLC6A9SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7896882 | 0.87 | SLC6A9 (0.61) | SLC6A9 | |
| Trifluoroacetic Acid SCHEMBL3089911 | 0.82 | SLC6A9 (0.55) | SLC6A9 | |
| SCHEMBL7888429 | 0.81 | SLC6A9 (0.74) | SLC6A9 | |
| Hydrochloric Acid SCHEMBL3106050 | 0.80 | SLC6A9 (0.73) | SLC6A9 | |
| SCHEMBL7887003 | 0.79 | SLC6A9 (0.62) | SLC6A9 | |
| Hydrochloric Acid SCHEMBL3101152 | 0.78 | SLC6A9 (0.61) | SLC6A9 | |
| SCHEMBL7896284 | 0.78 | SLC6A9 (0.64) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | claimed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | claimed |
| US-8563617-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-22 | — | — | US | claimed |
| EP-2396296-B1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBVIE DEUTSCHLAND (DE) | 2016-05-25 | — | — | EP | disclosed |
| US-9096619-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-04 | — | — | US | disclosed |
| US-9067871-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-01-30 | — | — | US | disclosed |
| US-8563617-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-22 | — | — | US | disclosed |
| US-8563617-B2 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-10-22 | — | — | US | disclosed |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AbbVie Deutschland GmbH & Co. KG (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | ABBVIE INC. | 2010-10-28 | — | — | US | disclosed |
| WO-2010092180-A1 | Aminotetraline derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT GMBH & CO. KG (DE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031331-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | SLC6A9 16/4885SLC6A2 44/4885SLC6A4 38/4885 |
| US-20100273739-A1 | Aminotetraline Derivatives, Pharmaceutical Composition, Containing Them, and Their Use in Therapy | AADAT, GFPT1, BCAT1 | SLC6A9 23/4885SLC6A2 48/4885SLC6A4 34/4885 |
| US-20130184238-A1 | AMINOTETRALINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | AADAT, GFPT1, BCAT1 | SLC6A9 16/4885SLC6A2 44/4885SLC6A4 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.